ClinicalTrials.gg
CompletedNCT00622648LIFENOXUpdated Dec 28, 2010

Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin

A Phase 4 interventional study of Enoxaparin and Placebo in Acute Illness, sponsored by Sanofi. Completed at 9 sites in 9 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2010-12-28.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8,329
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The primary objective:

  • To demonstrate in patients hospitalized for an acute medical illness that enoxaparin with Graduated Elastic Stockings is superior to enoxaparin-placebo with Graduated Elastic Stockings on overall mortality at day 30 after randomization.

The secondary objective:

  • To compare, in patients hospitalized for an acute medical illness, enoxaparin with Graduated Elastic Stockings versus enoxaparin placebo with Graduated Elastic Stockings on overall mortality at day 90 after randomization.
  • To evaluate the safety of enoxaparin VTE prophylaxis in patients hospitalized for acute medical illness with respect to major hemorrhage, total bleedings, heparin induced thrombocytopenia, adverse events and serious adverse events .
02

Conditions studied

  • Acute Illness

Keywords

  • Medical prevention therapy
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

List of inclusion and exclusion criteria

Inclusion criteria

Inclusion Criteria:

  • Hospitalization within 48 hours prior randomization for at least one of the following medical acute medical illness:

    • Acute decompensation of heart failure
    • Severe systemic infection and at least one of the following:

      • Chronic pulmonary diseases (, pulmonary fibrosis, pulmonary restrictive syndrome...)
      • Obesity ( ≥ 30kg/m2)
      • Personal history of VTE
      • Age ≥ 60 years
    • Active cancer (defined as being confirmed with an initial diagnosis or recurrence or within the past 6 months) excluding planned hospitalization for chemotherapy
  • Anticipated duration of hospitalization at least 6 days
  • Health status:

    • ASA Health status score ≤ 3 ()
    • ≤ 2 in cancer patient
  • Anticipated > 1 week

Exclusion criteria

Exclusion criteria:

  • Major surgery or major trauma within the previous 6 weeks (orthopedic or trauma surgery to the lower extremities, gastrointestinal tract, urological, chest, gynecological surgery)
  • Need for any ventilatory support (with intubation required)
  • Symptomatic VTE at enrollment
  • Multi organ failure
  • Evidence of an active bleeding disorder
  • to anticoagulation:

    • Coagulopathy (acquired or inherited)
    • Neurosurgery within the past day 30
    • History of cerebral hemorrhage at any time
    • Known bacterial endocarditis
    • Uncontrolled arterial hypertension (systolic BP > 200 mmHg or diastolic BP > 110 mm Hg) at 2 successive readings
    • Haemostatic abnormalities: baseline count \<50,000/mm3, (aPTT) 1.5x the , or International Normalized Ratio (INR) > 1.5
    • Indication for thrombolytic therapy
    • Need for a curative treatment of anticoagulant therapy (low molecular weight heparin, unfractionated heparin, oral anticoagulant therapy)
    • Receiving LMWH or UFH at prophylactic doses for more than 72 hours prior to inclusion (patients receiving LMWH or UFH at prophylactic doses for 72 hours or less prior to entry may be included in the study)
    • Oral anticoagulant therapy within 72 hours prior to inclusion
  • Cerebrovascular accident at inclusion and within 10 days prior study inclusion
  • Prosthetic heart valves
  • Confirmed cerebral
  • Known to heparin or LMWH, or pork-derived products
  • History of documented episode of heparin, or LMWH induced thrombocytopenia, and/or thrombosis (HIT, HAT, or HITTS)
  • Participating in another clinical trial within the previous 30 days (patients with cancer included in a cancer treatment protocol are authorized to participate)
  • Persistent renal failure (defined as a documented value of calculated \< 30 mL/min on at least 2 occasions ³3 days prior to entry into the study)
  • Known or suspected severe anemia of unexplained cause considered by investigator
  • Spinal or epidural analgesia or lumbar puncture within the preceding 24 hours
  • Unlikely to be compliant (e.g. alcohol, drug abuse)
  • Women of not protected by effective method of birth control and/or who are unwilling to be tested for pregnancy (pregnancy status should be checked by serum or urine pregnancy testing prior to exposure to the product)
  • Refusal or inability to give to participate in the study
  • Inability to be followed-up after discharge until day 90 after randomization

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
8,329 participants (actual)

Study arms

  • Experimental
    A

    Enoxaparin: 40 mg once daily for 6 to 14 days (10 ± 4 days)

    Drug: Enoxaparin

  • Placebo comparator
    B

    Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)

    Drug: Placebo

Interventions

  • 40 mg once daily for 6 to 14 days (10 ± 4 days)

  • DrugPlacebo

    Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)

06

What researchers measure

Primary outcomes

  1. Death rate with all causes mortality

    Time frame: At day 30

  2. Hemorrhages

    Time frame: Occuring until day 90

Secondary outcomes

  1. All-cause mortality

    Time frame: Between randomization and day 90

  2. Adverse events, serious adverse events

    Time frame: During the entire observation period (from informed consent signature until Day 90)

07

Study locations

9 sites
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Shanghai, China
  • Sanofi-Aventis Administrative Office
    Hong Kong, Hong Kong
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Seoul, Korea, Republic of
  • Sanofi-Aventis Administrative Office
    Kuala Lumpur, Malaysia
  • Sanofi-Aventis Administrative Office
    Col. Coyoacan, Mexico
  • Sanofi-Aventis Administrative Office
    Makati City, Philippines
  • Sanofi-Aventis Administrative Office
    Megrine, Tunisia
08

References and documents

Publications

  • Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011 Dec 29;365(26):2463-72. doi: 10.1056/NEJMoa1111288. PubMed 22204723 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2008, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2008
First posted
Feb 25, 2008
Start
Jan 2008
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Last update
Dec 28, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00622648
Lead sponsor
Sanofi
First posted
Feb 25, 2008
Start date
Jan 2008
Primary completion
Dec 2010
Completion
Dec 2010
Last update
Dec 28, 2010

Study contacts

Bruno DESLANDES
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin

Start the discussion